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Gy=1.7). Irradiation with C12 induced a strong increase of 
pRb expression (2 GyE=7.7, 7 GyE=8.3). There was a minimal 
change of p53 expression after RT (2 Gy=1.3; 7 Gy=1.2, 2 
GyE=1.6, 7 GyE=1.5). S12 cells (HPV 16 integrated) showed a 
decrease of pRB expression after RT with photons (2 Gy=0.47, 
7 Gy=0.38). Irradiation with C12 enhanced the expression of 
pRb positive cells (2 GyE= 1.8,7 GyE=1.94), but showed no 
significant expression of p53 in the control group. W12 cells 
(HPV 16 episomal) showed no change of pRb expression in the 
control group or after RT. C12 RT induced an increase of pRb 
expression (2 GyE=1.5, 7 Gy=2.9). There was no significant 
change of p53 expression in W12 and S12 cells after RT. C12-
RT showed no effect on cell cycle distribution in W12/S12 
and C33A cells. 48 h after irradiation with 7 Gy photons in 
C33A cells and 24 h after RT in S12 cells a G2/M-block was 
induced. 
Conclusions: The effect of carbon-ion-RT on protein 
expression seems to be dependent on HPV-status and type of 
protein with no effect on p53 or on HPV-negative cells, but a 
strong effect on pRb expression in HPV-positive cells. The 
converse effect of carbon-ion-RT compared to photon-RT on 
HPV positive cell with integrated HPV regarding pRb 
expression indicates that carbon-ion therapy might overcome 
HPV-integration induced radioresistance. 
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Purpose/Objective: Chemoradiation followed by a 
brachytherapeutic boost is standard of care for locally 
advanced cervical cancer (LACC). In the past, we 
implemented safely the use of neo-adjuvant chemoradiation 
using arc therapy. This allowed for a safe completion 
hysterectomy. This is a report on the long-term outcome 
results of this approach.  
Materials and Methods: Fifty-nine patients with LACC were 
treated (Figo IB: n=6; II: n= 41; III: n= 9; IV: n=3) between 
12/2005 and 08/2014. Chemotherapy, administered in 51 
patients (86%), consisted of weekly cisplatin (40mg/m2). 
Radiation consisted of an Intensity Modulated Arc Therapy 
delivered in 25 fractions. No neo-adjuvant brachytherapeutic 
treatment was performed. Dose prescription was: 62 Gy and 
60 Gy (Dmed) to the primary tumour and PET/CT-positive 
lymph nodes respectively; 45 Gy (minimal dose) to the 
uterus, cervix, upper vaginal 1/3 to ½, parametria and pelvic 
lymph nodes. Para-aortic irradiation was performed if N+ 
(n=22 or 37%). 
Six weeks after the neo-adjuvant chemoradiation a 
hysterectomy was performed. Suspected lymph nodes at the 
start of the treatment were resected selectively.  
Radiotherapeutic and surgical feasibility and the low 
morbidity/toxicity rates have been published before. 
Results: Median FU is 33 months (3-101m). Median age at 
diagnosis was 56y (21-89). Pathologic complete response rate 
is 36% (ypT0: 36%; ypT1a: 26,4%; ypT1b: 28,8%, ypT2a1: 1,7%; 
ypT2b: 6,8%). Lymphnode resection was performed in 29 
patients of which 6 had positive nodes. Surgical margins were 
free of disease in all but 2 cases (a brachytherapeutic boost 
was performed). Two- and 5-year local control rates are 94%. 
Two patients relapsed in a pelvic lymph node (2- and 5-year 
regional control = 96%). Two- and 5-year distant metastasis 
free survival is 91%. One patient developed a lung metastasis 
67 months after primary diagnosis, after resection no 
progression was noted. Two- and 5-year disease-specific 
survival are both 94% and 88%. Two- and 5-year OS are 88% 
and 69% (4/9 death causes were not cervical cancer related).  
Conclusions: Neo-adjuvant chemoradiation using modern 
radiotherapy techniques leads to promising control and 
survival rates. Further research should be considered to 
confirm these promising data. 
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Purpose/Objective: Wilms tumor or nephroblastoma is the 
most common primary renal tumor of children, with about 
500 cases per year in the United States. Treatment is 
individualized by tumor histology, stage, and a variety of 
biologic factors that help determine a patients' risk strata, 
and may include surgery, chemotherapy, and radiation 
therapy. This study sought to evaluate the outcomes for 
patients with Wilms tumor treated at a single institution. 
Materials and Methods: A retrospective review was 
performed of all children with Wilms tumor treated at a 
single institution from January 1994 through December 2012. 
Patients were staged by the NWTS system and managed on- 
or per- COG protocols. Stage I and II patients were generally 
managed with surgery and adjuvant chemotherapy. Stage III 
patients were generally managed with surgery followed by 
adjuvant chemotherapy and flank/abdominal radiotherapy. 
Stage IV patients were most commonly managed with 
surgery, chemotherapy, and flank/lung radiotherapy. Stage V 
patients generally received only surgery and chemotherapy. 
MedCalc was utilized to develop Kaplan-Meier plots of 
progression free and overall survival for the population. 
Results: Of the 64 treated patients, there were 7 patients 
with recurrence (10.9%). There were no recurrences in 11 
patients with stage I disease.  
There were 15 patients with stage II disease of which 3 
patients (20%) experienced recurrence. Two patients 
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experienced a local recurrence at 5 months and 22 months, 
respectively (one of these patients developed a second local 
recurrence 3 years after the first recurrence). One patient 
developed a lung metastasis 17 months after diagnosis. All 
recurrent stage II patients were treated and are alive with no 
evidence of disease (NED). 
Of 41 stage III patients, a recurrence was experienced in 3 
patients (7%). All of these recurrences were in the lung and 
were experienced at 4 months, 5 months, and 7 months after 
diagnosis. 
One out of eleven patients (9%) with stage IV disease 
experienced a recurrence. This was a local recurrence 
experienced 4 months after diagnosis. None of the 8 patients 
with stage V disease experienced a recurrence. Risk of 
progression based on stage is shown in the table below. 
The median time to failure was 6 months from diagnosis. Of 
the eight total recurrences (including 2 local recurrences in a 
single patient), 6 were salvaged and currently have no 
evidence of disease. Two patients are alive with active 
disease. 
Progression-free survival was 89%. Sixty three of the 64 
patients are still alive, giving an overall survival of 98.4%. 
The single patient who died had stage IV disease at diagnosis 
and experienced a recurrence prior to death. 
 
Stage PFS (%) OS (%) 
I 100 100 
II 80 100 
III 93 100 
IV 91 91 




Conclusions: Children with Wilms tumor can have excellent 
long-term outcomes when managed per NWTS/COG 
protocols. After 11 years of median follow up, PFS and OS 
were both excellent at 89% and 98.4%, respectively. 
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Purpose/Objective: To analyze the epidemiological 
characteristics of paediatric patients with Ewing's Sarcoma 
(ES) and assess the outcome (overall survival [OS] and disease 
free survival [DFS]) as well as potential prognostic factors 
associated with survival after the multidisciplinary 
treatment.  
Materials and Methods: Retrospective study of paediatric 
patients with ES treated during the period 1979-2014. SPSS 
19.0 was used for statistical analysis and Kaplan-Meier's 
method for the analysis of survival. The potential risk factors 
were assessed using univariate and multivariate analyses. 
Results: During the last 35 years, 102 patients were treated 
at our Institution. Male patients were 55.8% and the median 
age was 10.5 years (range 2-19). The pain was the most 
common symptom at initial presentation. Non-axial location 
was observed in 62.8% of patients and non-metastatic or 
multicentric disease in 83.3%. The median time between the 
onset of symptoms and the date of diagnosis was 3.07 months 
(range: 0.1- 36.5 months). 68.7% received surgery, 49% 
radiotherapy (with radical intention, before or after surgery) 
and 25.5 % hematopoietic stem cell transplantation. The 2 
and 5-years OS was 81 % and 57 %, respectively. Two and five 
years DFS was 68% and 54%, respectively. Local recurrence 
occurred in 11.8 % and distant relapse in 36.2 % of patients. 
Secondary malignancies occurred in 5% of patients (2 acute 
myeloblastic leukemia, 2 myelodysplastic syndromes and one 
pleomorphic sarcoma). Risk factors for OS observed in the 
univariate analysis were: an erythrocyte sedimentation rate 
at diagnosis > median (Median 43; HR: 4.42, p = 0.02), the 
lack of surgery (HR 1.97, p = 0.024), poor pathological 
responder (> 10% viable tumor) to induction chemotherapy 
(HR 2.88, p = 0.012), the use of cobalt units vs. linear 
accelerators (HR 2.93, p = 0.009) and the response to 
multidisciplinary treatment (progression versus rest of 
responses; HR 6.52, p <0.001). In multivariate analysis only 
the radiotherapy units (HR 4,21, p = 0,030) and the response 
to treatment (Response vs progression: HR 0,10, p < 0,001) 
retained statistically significance. 
Conclusions: Our results suggest that paediatric patients with 
ES who have a good response to the multidisciplinary 
treatment or those treated with linear accelerators vs cobalt 
units have a lower risk of mortality. Therefore, it seems that 
technological development has contributed to improve the 
survival in these patients.  
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